Small Cell Lung Carcinoma — Clinical Trials

MONDO:0008433269 active·145 recruitingLast updated: Mar 17, 2026, 8:39 PM

Trial Landscape

Small Cell Lung Carcinoma has one of the most active rare disease trial programs, driven by drug treatment and procedure.

145

Recruiting

269

Active Trials

By Approach

Drug Treatment268

Procedure51

Biological Therapy29

Medical Device9

Gene Therapy1

69 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

167

Phase 3

Phase 4

83 trials are observational or have no phase designation.

Sponsor Types

Academic/Other190Industry151NIH7Collaborative Network5Federal3

Top Sponsors

AbbVie

Abbisko Therapeutics Co, Ltd

Advenchen Laboratories, LLC

Advenchen Pharmaceuticals, LLC.

Akeso

Allist Pharmaceuticals, Inc.

Trial Locations

United States147 trials

China137 trials

Spain58 trials

Italy51 trials

France50 trials

South Korea44 trials

Japan42 trials

Canada41 trials

Germany40 trials

Australia34 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

500 Trials

Phase 3Recruiting

NCT07195695

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Sponsor:Boehringer IngelheimOrphan Designation

United StatesStarted: Jan 2026Est. completion: Sep 2036Updated: Mar 2026

Phase 3Recruiting

NCT06793215

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Sponsor:Hoffmann-La Roche

United StatesStarted: Oct 2025Est. completion: Oct 2030Updated: Mar 2026

Phase 3Recruiting

NCT06687369

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Sponsor:mAbxience Research S.L.

ArmeniaStarted: Dec 2024Est. completion: Sep 2027Updated: Mar 2026

Phase 3Recruiting

NCT06430866

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Sponsor:AmgenOrphan Designation

ArgentinaStarted: Sep 2024Est. completion: Dec 2026Updated: Mar 2026

Phase 3Recruiting

NCT06452277

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Sponsor:Bayer

United StatesStarted: Aug 2024Est. completion: Jun 2029Updated: Mar 2026

Phase 3Recruiting

NCT06417814

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor:AstraZeneca

United StatesStarted: Oct 2024Est. completion: Sep 2028Updated: Mar 2026

Phase 3Recruiting

NCT05671510

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Sponsor:OncoC4, Inc.

United StatesStarted: Jun 2023Est. completion: Aug 2028Updated: Feb 2026

Phase 3Recruiting

NCT06930794

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Sponsor:Beijing Pearl Biotechnology Limited Liability Company

ChinaStarted: Jul 2025Est. completion: Feb 2030Updated: Jan 2026

Phase 3Recruiting

NCT05522660

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Sponsor:ETOP IBCSG Partners Foundation

ItalyStarted: Nov 2022Est. completion: Dec 2026Updated: Dec 2025

Phase 3Recruiting

NCT06416410

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Sponsor:Allist Pharmaceuticals, Inc.

ChinaStarted: Aug 2024Est. completion: Feb 2027Updated: Apr 2025

Phase 3Active, Not Recruiting

NCT04379635

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Sponsor:BeiGene

ChinaStarted: May 2020Est. completion: Mar 2027Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT04205812

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Sponsor:Incyte Corporation

United StatesStarted: Sep 2020Est. completion: Aug 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT06396065

Phase III Study of AK112 for NSCLC Patients

Sponsor:Summit Therapeutics

United StatesStarted: May 2023Est. completion: Dec 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT06624059

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Sponsor:Hoffmann-La Roche

AustraliaStarted: Nov 2024Est. completion: Mar 2033Updated: Jan 2026

Phase 3Active, Not Recruiting

NCT03703297

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Sponsor:AstraZeneca

United StatesStarted: Sep 2018Est. completion: Oct 2026Updated: Nov 2025

Phase 3Active, Not Recruiting

NCT06348199

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Sponsor:Samsung Bioepis Co., Ltd.

Bosnia and HerzegovinaStarted: Mar 2024Est. completion: Sep 2026Updated: Nov 2025

Phase 3Active, Not Recruiting

NCT03043872

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Sponsor:AstraZeneca

United StatesStarted: Mar 2017Est. completion: Dec 2025Updated: Oct 2025

Phase 3Active, Not Recruiting

NCT06505837

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Sponsor:Shanghai Junshi Bioscience Co., Ltd.

ChinaStarted: Jul 2024Est. completion: Dec 2026Updated: Aug 2025

Phase 3Active, Not Recruiting

NCT04154956

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Sponsor:Sanofi

United StatesStarted: Feb 2020Est. completion: Mar 2026Updated: Aug 2025

Phase 3Active, Not Recruiting

NCT04746924

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Sponsor:BeiGene

United StatesStarted: Jun 2021Est. completion: Mar 2026Updated: Jun 2025

Stay informed about clinical trials for Small Cell Lung Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 17, 2026 at 8:39 PM

Small Cell Lung Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

500 Trials

Open Trials201

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Active Trials68

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Phase III Study of AK112 for NSCLC Patients

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Other231